# Inovio Pharmaceuticals

Inovio Pharmaceuticals is an Asset Manager based in Plymouth Meeting, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Plymouth Meeting, United States
- **Region:** North America
- **Address:** Plymouth Meeting, PA, United States
- **Assets under management:** Undisclosed
- **Website:** www.inovio.com
- **LinkedIn:** https://www.linkedin.com/company/inovio-pharmaceuticals

## Regulatory record

- **Reports private funds:** No

## About

INOVIO is advancing novel immunotherapy technologies to reshape the future of treating and preventing infectious diseases and cancer.

## Sectors

- Biotech
- Immunotherapy
- DNA Medicine
- Oncology
- Infectious Disease

## Offices

- San Diego, CA, United States

## People

- Jacqueline Shea — President & Chief Executive Officer
- Laurent Humeau — Chief Scientific Officer
- Peter Kies — Chief Financial Officer
- Michael Sumner — Chief Medical Officer & Head of Development
- Steve Egge — Chief Commercial Officer

## Questions

### Who runs investment decisions at Inovio Pharmaceuticals?

Jacqueline Shea, Ph.D., is President and CEO, leading corporate strategy and investment allocation. The executive team includes Chief Scientific Officer Laurent Humeau, Chief Medical Officer Michael Sumner, and CFO Peter Kies. No external investment committee is disclosed.

### How does Inovio Pharmaceuticals source proprietary deal flow?

Inovio develops its pipeline internally via its DNA medicine platform and proprietary CELLECTRA® delivery devices. Business development is handled by an internal team (per the firm's website contact page). No external deal flow networks are specified.

### What investment stages does Inovio Pharmaceuticals typically target?

Inovio is a clinical-stage company; its pipeline ranges from discovery through late-stage clinical development. The lead candidate INO-3107 is under FDA BLA review, approaching potential commercialization. The firm also pursues partnerships for earlier-stage candidates.

### Which sectors does Inovio Pharmaceuticals explicitly avoid?

Inovio does not publicly state specific sectors it avoids. Its focus is DNA-based immunotherapies and vaccines for oncology and infectious diseases, with no disclosed activity in gene editing or RNA-based therapies.

## Related profiles

- [Ninja Partners Inc.](https://altss.com/profile/ninja-partners-inc)
- [Hannover Digital Investments GmbH](https://altss.com/profile/hannover-digital-investments-gmbh)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/inovio-pharmaceuticals

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology